Ocular Therapeutix, Inc.
NASDAQ:OCUL
7.06 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 63.723 | 58.443 | 51.494 | 43.522 | 17.403 | 4.227 | 1.99 | 1.923 | 1.887 | 1.75 | 0.772 | 0 | 0.01 |
| Cost of Revenue
| 5.626 | 5.281 | 4.54 | 4.406 | 2.083 | 2.325 | 0.465 | 0.457 | 0.443 | 0.319 | 0.091 | 10.517 | 0.007 |
| Gross Profit
| 58.097 | 53.162 | 46.954 | 39.116 | 15.32 | 1.902 | 1.525 | 1.466 | 1.444 | 1.431 | 0.681 | -10.517 | 0.003 |
| Gross Profit Ratio
| 0.912 | 0.91 | 0.912 | 0.899 | 0.88 | 0.45 | 0.766 | 0.762 | 0.765 | 0.818 | 0.882 | 0 | 0.3 |
| Reseach & Development Expenses
| 127.635 | 61.055 | 53.462 | 50.083 | 28.694 | 41.091 | 36.915 | 30.88 | 27.065 | 26.611 | 18.88 | 10.517 | 11.54 |
| General & Administrative Expenses
| 60.653 | 33.94 | 32.224 | 31.88 | 22.859 | 22.122 | 18.786 | 15.509 | 11.004 | 9.165 | 6.913 | 1.761 | 1.477 |
| Selling & Marketing Expenses
| 41.59 | 40.549 | 39.922 | 35.19 | 26.614 | 24.491 | 4.942 | 17 | 6.701 | 3.852 | 1.982 | 0.625 | 0.657 |
| SG&A
| 102.243 | 74.489 | 72.146 | 67.07 | 49.473 | 46.613 | 23.728 | 32.509 | 17.705 | 13.017 | 8.895 | 2.386 | 2.134 |
| Other Expenses
| 0 | 0 | -0.001 | 0.001 | 0 | -0.008 | 0 | 0.005 | -0.001 | 0.007 | -0.442 | 0.014 | -0.049 |
| Operating Expenses
| 229.878 | 135.544 | 125.608 | 117.153 | 78.167 | 87.704 | 60.643 | 63.389 | 44.77 | 39.628 | 27.775 | 12.903 | 13.674 |
| Operating Income
| -171.781 | -82.382 | -78.654 | -78.037 | -62.847 | -85.802 | -59.118 | -61.923 | -43.326 | -38.197 | -27.094 | -12.903 | -13.671 |
| Operating Income Ratio
| -2.696 | -1.41 | -1.527 | -1.793 | -3.611 | -20.299 | -29.708 | -32.201 | -22.96 | -21.827 | -35.096 | 0 | -1,367.1 |
| Total Other Income Expenses Net
| -21.725 | 1.646 | 7.616 | 71.484 | -92.789 | -0.57 | -0.86 | -1.463 | -1.377 | -1.551 | -1.554 | -0.414 | -0.422 |
| Income Before Tax
| -193.506 | -80.736 | -71.038 | -6.553 | -155.636 | -86.372 | -59.978 | -63.386 | -44.703 | -39.748 | -28.648 | -13.317 | -14.093 |
| Income Before Tax Ratio
| -3.037 | -1.381 | -1.38 | -0.151 | -8.943 | -20.433 | -30.14 | -32.962 | -23.69 | -22.713 | -37.109 | 0 | -1,409.3 |
| Income Tax Expense
| 0 | 0 | -7.616 | 4.251 | 3.995 | 3.563 | -2.286 | 0.272 | 0.798 | 0.977 | 0.13 | 0.455 | 0.328 |
| Net Income
| -193.506 | -80.736 | -63.422 | -10.804 | -159.631 | -89.935 | -57.692 | -63.386 | -44.703 | -39.748 | -28.648 | -13.317 | -14.093 |
| Net Income Ratio
| -3.037 | -1.381 | -1.232 | -0.248 | -9.173 | -21.276 | -28.991 | -32.962 | -23.69 | -22.713 | -37.109 | 0 | -1,409.3 |
| EPS
| -1.22 | -1.09 | -0.83 | -0.14 | -2.63 | -1.99 | -1.51 | -2.2 | -1.8 | -1.71 | -2.69 | -4.51 | -4.77 |
| EPS Diluted
| -1.22 | -1.02 | -0.83 | -0.13 | -2.63 | -1.99 | -1.51 | -2.2 | -1.8 | -1.71 | -2.69 | -4.51 | -4.77 |
| EBITDA
| -176.143 | -66.415 | -61.907 | -75.616 | -146.095 | -77.741 | -55.953 | -59.869 | -42.142 | -37.27 | -26.982 | -12.499 | -13.312 |
| EBITDA Ratio
| -2.764 | -1.136 | -1.202 | -1.737 | -8.395 | -18.392 | -28.117 | -31.133 | -22.333 | -21.297 | -34.951 | 0 | -1,331.2 |